90.33 0.00 (0.00%)
After hours: 5:13PM EST
|Bid||90.30 x 800|
|Ask||90.30 x 900|
|Day's Range||90.00 - 90.56|
|52 Week Range||73.54 - 95.00|
|Beta (3Y Monthly)||0.51|
|PE Ratio (TTM)||17.83|
|Forward Dividend & Yield||2.83 (3.15%)|
|1y Target Est||101.00|
Novartis CEO Vasant Narasimhan and UPS CEO David Abney weigh in on the speed of innovation and the specifics of how their companies will improve experiences for customers.
Novartis is exiting drug discovery at its Shanghai site and shifting its focus to drug development, saying accelerating approvals in China are pushing the Swiss company to dedicate the operation's resources to getting its medicines to market. The move marks an about-face from just three years ago, when Novartis had christened the $1 billion campus as its Chinese hub for early-stage research. About 150 of the more than 1,000 Shanghai staffers will lose their research jobs, while Novartis plans to add 340 new positions to develop up-and-coming drug prospects over the next four years, a period in which it expects to file 50 new drug applications with China's regulator.
Novartis is halting early-stage research in Shanghai and shifting the site's focus to commercial development three years after the Swiss drugmaker christened the new $1 billion campus as its Chinese drug discovery hub. About 150 of some 1,300 Shanghai staffers will lose their research jobs, while Novartis plans to add 340 new positions over the next four years to develop up-and-coming drug prospects. The changes, first reported by website Fierce Biotech, were confirmed by Novartis.
Boston’s Biofourmis Inc. is acquiring longtime partner Biovotion, leveraging its software and data-collection capabilities in a new multi-year partnership with Novartis.
Despite the issues that have bubbled up related to its breakthrough drug for spinal muscular atrophy, Zolgensma, Novartis "has the newest pipeline with many drugs just beginning to have an impact ...
The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said. The biologic drug, also known as crizanlizumab, was shown in trials in its high-dose formula to cut sickle cell pain crises nearly by half to 1.63 incidents annually from 2.98 in those getting a placebo. Novartis has forecast that the drug's annual sales will top $1 billion, much of which will likely come from U.S. government payers such as Medicare and Medicaid.
Novartis AG on Friday won U.S. approval for its experimental sickle cell disease drug, Adakveo, making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. regulatory clearance. The drug will be priced between $84,852 and $113,136 per year for most patients, who will be infused by a healthcare provider with between three and four vials each month, Novartis said. The biologic drug, also known as crizanlizumab, was shown in trials in its high-dose formula to cut sickle cell pain crises nearly by half to 1.63 incidents annually from 2.98 in those getting a placebo.
Drug giant Roche is buying another Boston area biotech startup, this time paying $390 million upfront for the company’s treatments for tissue scarring.
Local rare disease drugmaker Sarepta Therapeutics Inc. is expanding its efforts in the gene therapy field, signing a deal this week with a North Carolina startup to develop up to eight new treatments.
One of the biggest players in the Boston area’s biotech and life sciences field has snagged one of Novartis’ top dealmakers as it pushes for more early-stage collaborations.
Biogen stock popped in mid-October after the biotech company said a broader analysis showed some promise for its Alzheimer's treatment, aducanumab. Is now the time to buy Biogen stock?
Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day
Novartis is buying the Japanese generics unit of South Africa's Aspen Pharmacare in a deal worth up to 400 million euros ($440.80 million) to expand in the world's third-biggest drug market, the Swiss drugmaker said on Monday. Novartis's Sandoz generics business agreed to pay 300 million euros initially, plus a deferred amount not expected to exceed 100 million euros based on certain conditions being met, Novartis said.
Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study. Roche, which plans to seek approval for the investigational medicine this year, said its SUNFISH trial demonstrated statistically significant improvements in patients aged 2-25 years with Type 2 or 3 SMA, compared to a placebo. Biogen's Spinraza, approved in 2016, lists at $750,000 in year one and $375,000 thereafter, while Novartis's Zolgensma is the costliest one-time treatment at $2.1 million.
NEW YORK, Nov. 09, 2019 -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG.